#non-nucleoside reverse transcriptase inhibitor

Celebrating 20 years of effective HIV treatment

Here’s a timeline of the highlights.

People contracting HIV are increasingly acquiring strains that are resistant to antiretrovirals (ARVs).

HIV treatment taken only every two months is moving closer to reality.

ViiV Healthcare is beginning Phase III trials of the integrase inhibitor Tivicay and the non-nucleoside reverse transcriptase inhibitor Eduran...

Merck’s next-generation NNRTI doravirine (MK-1439) suppresses HIV as well as Sustiva (efavirenz) and leads to half the rate of side effects.

Merck’s investigatory non-nuke MK-1439 proved safe and well tolerated—and it displayed robust antiviral activity in a small early trial.

Lersivirine, ViiV Healthcare’s experimental NNRTI, achieves similar rates of viral load suppression compared with Sustiva (efavirenz).